Chen, Kuei-An
Huang, Wei-Ming
Chen, Eric Yi-Ting
Ho, Pei-Kuan
Chueh, Chen-Han
Wen, Yu-Wen
Chen, Ming-Huang
Chiang, Nai-Jung
Tsai, Yi-Wen
Article History
Received: 28 January 2024
Accepted: 9 May 2024
First Online: 22 May 2024
Declarations
:
: The study was approved by the Institutional Review Board (IRB) of Taipei Veterans General Hospital, Taiwan (No. 2023-01-018CC). The procedures conducted in studies involving human participants adhered to the ethical guidelines set forth by the institutional and/or national research committee, as well as the 1964 Helsinki Declaration and its subsequent revisions, or equivalent ethical standards. The IRB of Taipei Veterans General Hospital has granted a waiver for participant consent in this research owing to its low-risk nature. Additionally, the potential risk to research participants is no greater than that to non-participants, and the exemption from obtaining prior consent does not impact the rights and interests of the research participants.
: Not applicable.
: Nai-Jung Chiang received payments for lectures from TTY Biopharm Company Limited; Ono Pharmaceutical Co., Ltd.; Bristol Myers Squibb; and PharmaEngine, Inc. Kuei-An Chen, Wei-Ming Huang, Eric Yi-Ting Chen, Pei-Kuan Ho, Chen-Han Chueh, Yu-Wen Wen, Ming-Huang Chen, and Yi-Wen Tsai declare that they have no conflicts of interest.